144 Participants Needed

RAY121 for Immune System Disorders

Recruiting at 65 trial locations
Ct
Overseen ByClinical trials information
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

Will I have to stop taking my current medications?

The trial protocol does not specify if you must stop taking your current medications, but it mentions that certain treatments are prohibited. It's best to discuss your current medications with the trial team to see if they fall under the prohibited category.

What data supports the effectiveness of the drug RAY121 for immune system disorders?

Research on rituximab, a drug similar to RAY121, shows it can be effective in treating severe autoimmune diseases in children, suggesting potential benefits for immune system disorders.12345

What makes the drug RAY121 unique for treating immune system disorders?

RAY121 is unique because it involves the use of IL-12, a cytokine that can modulate the immune system by promoting T helper type 1 (Th1) cell responses, which are crucial for fighting infections and tumors. This mechanism of action is different from many existing treatments, as IL-12 can directly enhance the immune response and potentially overcome immune suppression seen in certain conditions.678910

What is the purpose of this trial?

This trial is testing a new drug called RAY121, which aims to help people with certain immune system diseases by blocking a part of the immune system that causes inflammation. The trial will check if the drug is safe and effective for patients with conditions like APS, BP, BS, DM, IMNM, and ITP.

Research Team

SC

Sponsor Chugai Pharmaceutical Co.Ltd

Principal Investigator

clinical-trials@chugai-pharm.co.jp

Eligibility Criteria

This trial is for people with certain immune system disorders like low platelet count, antiphospholipid syndrome, dermatomyositis, Behcet's Disease, and bullous pemphigoid. Participants should have one of these conditions to join the study.

Inclusion Criteria

Ability to comply with the study protocol
Signed informed consent form
APS cohort: Established primary APS defined by specific laboratory and clinical criteria
See 7 more

Exclusion Criteria

I have an autoimmune disease that is not the disease this trial is targeting.
I have not received any treatments that are not allowed in this study.
My liver tests are high.
See 22 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive multiple doses of RAY121 to assess safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary efficacy

32 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

  • RAY121
Trial Overview The RAINBOW Trial is testing a new medication called RAY121 to see if it's safe and how well it works in treating various immunological diseases by inhibiting part of the body's immune response.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: RAY121Experimental Treatment1 Intervention
All enrolled patients will receive RAY121 multiple dose

Find a Clinic Near You

Who Is Running the Clinical Trial?

Chugai Pharmaceutical

Lead Sponsor

Trials
105
Recruited
25,000+

Dr. Osamu Okuda

Chugai Pharmaceutical

Chief Executive Officer since 2020

MD from Kyoto University

Dr. Mariko Y. Momoi

Chugai Pharmaceutical

Chief Medical Officer

MD from Jichi Medical University

Findings from Research

In a study of 7 children with refractory autoimmune cytopenia, rituximab treatment resulted in a 71% response rate, with 4 patients achieving complete responses and 1 achieving a partial response.
Rituximab was well tolerated, with no serious adverse events reported, and responders experienced a significant reduction in their previous treatments.
[Role of rituximab in the management of refractory autoimmune cytopenia].Losa Frías, V., García Sánchez, AM., Ortiz Valentín, I., et al.[2015]
Rituximab, an anti-CD20 monoclonal antibody, showed an acceptable safety profile in a study of 10 pediatric patients with severe autoimmune diseases, although there were serious infections in three patients and one death related to underlying conditions.
The treatment led to significant clinical improvements in nine patients, allowing for a median reduction of 63% in corticosteroid use, with some patients achieving complete discontinuation of steroids, although not all maintained long-term benefits.
Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases.El-Hallak, M., Binstadt, BA., Leichtner, AM., et al.[2019]
A 68-year-old male with squamous cell lung cancer experienced Stevens-Johnson syndrome (SJS) after a single dose of pembrolizumab, but treatment with steroids led to complete remission of his cancer, suggesting that managing immune-related adverse events can be crucial for patient outcomes.
The case highlights the potential role of Nr4a1 mRNA suppression in enhancing antitumor immunity, as changes in immune response markers (like IFN-γ and IL-17) correlated with the patient's recovery, indicating that monitoring these indices could help guide future immunotherapy interventions.
A case report involving suppressed nuclear receptor transcription factors 4a1 and Stevens-Johnson syndrome induced by a single dose of pembrolizumab and successfully treated with early steroid administration, resulting in complete remission of stage III lung cancer.Machida, M., Yamazaki, C., Kouda, N., et al.[2022]

References

[Role of rituximab in the management of refractory autoimmune cytopenia]. [2015]
Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases. [2019]
A case report involving suppressed nuclear receptor transcription factors 4a1 and Stevens-Johnson syndrome induced by a single dose of pembrolizumab and successfully treated with early steroid administration, resulting in complete remission of stage III lung cancer. [2022]
Durable Metastatic Melanoma Remission Following Pembrolizumab and Radiotherapy: A Case Report of Prophylactic Immunosuppression in a Patient with Myasthenia Gravis and Immune-Mediated Colitis. [2022]
Added value of combining methotrexate with a biological agent compared to biological monotherapy in rheumatoid arthritis patients: A systematic review and meta-analysis of randomised trials. [2020]
The regulation and activity of interleukin-12. [2022]
Interleukin-12, a key cytokine in Th1-mediated autoimmune diseases. [2005]
Endogenous IL-12 triggers an antiangiogenic program in melanoma cells. [2022]
Lack of Il12rb2 signaling predisposes to spontaneous autoimmunity and malignancy. [2021]
B-cell acute lymphoblastic leukemia promotes an immune suppressive microenvironment that can be overcome by IL-12. [2022]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security